NewDEL Biotech Secures Tens of Millions of RMB in Series A Financing to Advance DEL+X Platform and Class 1 New Drug ND-003 into Clinical Trials

VCBeat learned that Shenzhen NewDEL Biotech Co., Ltd. (hereinafter referred to as "NewDEL Biotech") announced the completion of a multi-million RMB A-round financing. The investor in this round was ZHUHAI HECHENGZHIYI CAPITAL MANAGEMENT CO., LTD.This continued investment boost is both a recognition of NewDEL Biotech's past achievements and an expectation of its future development potential. The funds from this round of financing will be used to accelerate the domestic Phase I clinical trial of the innovative drug ND-003 project in China, the construction of the DEL+X technology platform (including DEL+AI, i.e., SMART DEL, DEL+protac, and DEL+molecular probes), as well as for the preclinical and early clinical development of other projects within the company.

NewDEL Biotech is the first biopharmaceutical company incubated by the Guangdong Small Molecule New Drug Innovation Center. It possesses the world's leading DEL live cell screening technology and continuously develops the DEL+X technology platform, including SMART DEL, DEL+protac, and DEL+molecular probes.

Since its establishment more than two years ago, it has made remarkable progress in various aspects such as team building, technology platform construction, pipeline layout, and external cooperation, includingBuilt a full industrial chain team for new drug development from the DEL Technology Center to the Business Market Department, constructed the DEL+X technology platform and dozens of R&D pipelines, obtained four clinical trial approvals filed in both China and the U.S., with the first clinical dosing completed in early February. Secured multi-million-dollar order collaborations with publicly listed pharmaceutical companies.

In 2023, the investment enthusiasm in the biopharmaceutical industry plummeted, with many investment institutions completely withdrawing from the biopharmaceutical sector. The entire new drug development field has entered a "rapid freeze" period in terms of financing. However, the success of this Series A round of financing once again demonstrates the capital market's recognition and trust in the R&D team and capabilities of NewDEL Biotech. This round of investment will further accelerate the company’s progress in research and clinical trials.

For the acquisition of this round of financing,Mr. He Xun, Founder and Chairman of NewDEL BiotechExpressed: Deep gratitude to the old shareholder and ZHUHAI HECHENGZHIYI CAPITAL MANAGEMENT CO., LTD. for their trust and support in NewDEL Biotech's innovative R&D capabilities, clinical development capabilities, and future commercialization potential. The proceeds from this round of financing will provide significant support for further enhancement of the company’s technology platform, clinical development of First-in-class innovative drugs, and initiation and advancement of new pipelines. Over the past year, despite experiencing a capital winter, the company has relied on its solid technical reserves and R&D resources to address unmet clinical needs, building a competitive and differentiated drug R&D pipeline and technology platform. Notable achievements have been made in project advancement and external collaborations. The core team of NewDEL Biotech will continue to adhere to a forward-looking innovation strategy with differentiated positioning, focusing intently on research, meticulously planning, and wholeheartedly executing. The goal is to develop effective medicines for patients, generate returns for investors, and drive the company’s growth.

ZHUHAI HECHENGZHIYI CAPITAL MANAGEMENT CO., LTD.Expressed: We are very pleased to have the opportunity to support the development of NewDEL Biotech through this round of investment. Based on a profound understanding of small molecule drugs, NewDEL Biotech has built a highly competitive technology platform, focusing on unmet clinical needs and independently developing innovative drugs with internationally leading standards. Despite the overall challenges faced by China's innovative drug industry, NewDEL Biotech’s innovation capability, efficient team execution, highly collaborative pipeline layout, and inspiring data strongly demonstrate the company’s value and development potential. ZHUHAI HECHENGZHIYI CAPITAL MANAGEMENT CO., LTD. is committed to assisting the growth of companies with global technological innovations. We have high expectations for NewDEL Biotech’s future R&D progress and clinical advancement, and look forward to even greater achievements post-investment.

ZHUHAI HECHENGZHIYI CAPITAL MANAGEMENT CO., LTD. (Hecheng Capital) was founded in 2015 as a professional investment management firm dedicated to long-term value investing. As a venture capital institution, the company upholds the core values of "Harmony and Cooperation, Integrity as the Foundation," focusing on investing in and incubating innovative enterprises with "core technology" while nurturing and empowering leading "chain leader" enterprises. It has successfully invested in multiple high-tech companies specializing in information technology, advanced manufacturing, new materials, and biopharmaceuticals.